When insiders accumulate a stock intensively, the stock can be expected to outperform the market during the next six months. Insiders tend to buy more often than usual before large price increases and to sell more than usual before price decreases.
In this article, I will feature one biotech company that has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:
The stock is purchased by three or more insiders within one month.
The stock is sold by no insiders in the month of intensive purchasing.
At least two purchasers increase their holdings by more than 10%.
BioTime (BTX), a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders.
Insider buying by insider (last 30 days)
- Franklin Berger purchased 500 shares on August 20 and currently holds 500 shares or less than 0.1% of the company. Franklin Berger serves as a director of the company.
- Stephen Farrell purchased 4,187 shares on August 19-20 and currently holds 4,187 shares or less than 0.1% of the company. Stephen Farrell serves as a director of the company.
- Andrew von Eschenbach purchased 3,000 shares on August 12 and currently holds 3,000 shares or less than 0.1% of the company. Andrew von Eschenbach serves as a director of the company.
Insider buying by calendar month
Here is a table of BioTime's insider-trading activity by calendar month.
| Month | Insider buying / shares | Insider selling / shares |
| August 2013 | 7,687 | 0 |
| July 2013 | 0 | 0 |
| June 2013 | 0 | 0 |
There have been 7,687 shares purchased and there have been zero shares sold by the insiders since June 2013.
Financials
The company reported the second-quarter financial results on August 9 with the following highlights:
| Revenue | $1.0 million |
| Net |
